Results 11 to 20 of about 143,566 (359)
Acta Pharmaceutica Sinica B, 2023 The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy.
Qingqing Xiao +9 more
doaj +1 more source
Cancer Immunotherapy: Beyond Checkpoint Blockade [PDF]
Annual Review of Cancer Biology, 2019 Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be inhibited by immunosuppressive mechanisms within the tumor, often through pathways outside of the currently targeted checkpoints.
Michael, Dougan +2 more
openaire +2 more sources
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]
, 2016 PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R. +13 more
core +6 more sources
Hyperprogression: A novel response pattern under immunotherapy
Clinical and Translational Medicine, 2020 Checkpoint blockade therapy has shown significant therapeutic benefits and resulted in durable responses in patients with various tumors. However, accumulating evidence has demonstrated that 4‐29% of all patients with cancers with various histologies may
Xue‐jiao Han +4 more
doaj +1 more source
Nature Communications, 2021 Immune-checkpoint blockade has shown limited benefits in patients with glioblastoma. To understand how the composition of the tumor immune microenvironment might limit clinical responses, here the authors present a high dimensional profiling of the ...
Alexander H. Lee +13 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2021 Extrinsic factors such as expression of PD-L1 (programmed dealth-ligand 1) in the tumor microenvironment (TME) have been shown to correlate with responses to checkpoint blockade therapy.
Bjarne Bartlett +11 more
doaj +1 more source
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy [PDF]
, 2019 Natural killer (NK) cells are lymphocytes of the innate immune response characterized by their role in the destruction of tumor cells. Activation of NK cells depend on a fine balance between activating and inhibitory signals mediated by different ...
Alonso, Corona +12 more
core +1 more source
Radiotherapy Complements Immune Checkpoint Blockade [PDF]
Cancer Cell, 2015 Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated by non-redundant immune mechanisms ...
Ngiow, Shin Foong +2 more
openaire +3 more sources
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul +11 more
core +1 more source
Immune checkpoint blockade in HIV
eBioMedicine, 2022 Antiretroviral therapy (ART) has dramatically improved life expectancy for people with HIV (PWH) and helps to restore immune function but is not curative and must be taken lifelong. Achieving long term control of HIV in the absence of ART will likely require potent T cell function, but chronic HIV infection is associated with immune exhaustion that ...
Gubser, C +3 more
openaire +5 more sources